CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
76.65
-0.38 (-0.49%)
Aug 12, 2026, 1:43 PM EDT - Market open
CG Oncology Revenue
CG Oncology had revenue of $1.16M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $6.23M, up 1,030.31% year-over-year. In the year 2025, CG Oncology had annual revenue of $4.04M with 254.70% growth.
Revenue (ttm)
$6.23M
Revenue Growth
+1,030.31%
P/S Ratio
1,096.33
Revenue / Employee
$43,859
Employees
142
Market Cap
6.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.04M | 2.90M | 254.70% |
| Dec 31, 2024 | 1.14M | 935.00K | 458.33% |
| Dec 31, 2023 | 204.00K | 13.00K | 6.81% |
| Dec 31, 2022 | 191.00K | -10.17M | -98.16% |
| Dec 31, 2021 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.01B |
| Caris Life Sciences | 989.61M |
| TG Therapeutics | 799.54M |
| Mirum Pharmaceuticals | 618.07M |
| Xenon Pharmaceuticals | 7.50M |
| Dianthus Therapeutics | 1.90M |
CGON News
- 5 days ago - CG Oncology price target raised to $85 from $82 at Truist - TheFly
- 5 days ago - CG Oncology price target lowered to $79 from $81 at RBC Capital - TheFly
- 6 days ago - CG Oncology reports Q2 EPS (90c), consensus (64c) - TheFly
- 6 days ago - CG Oncology Earnings release: Q2 2026 - Filings
- 6 days ago - CG Oncology Quarterly report: Q2 2026 - Filings
- 6 days ago - CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 15 days ago - CG Oncology announces publication of BOND-003 results in The Lancet Oncology - TheFly
- 15 days ago - CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology - GlobeNewsWire